Core Viewpoint - The article discusses a large-scale healthcare fraud case involving hemophilia patients, pharmaceutical representatives, and private hospitals in Zhejiang, China, highlighting the complexities of healthcare reimbursement policies and the ethical dilemmas faced by patients and medical professionals [1][2][20]. Group 1: Fraud Scheme Details - The fraud scheme involved pharmaceutical representatives, private hospitals, and dispensing companies colluding to induce patients to falsely claim medical expenses for hemophilia medications, leading to significant financial losses for the healthcare system [1][13][15]. - Patients were offered incentives, such as a 4% rebate on medication purchases, which encouraged them to participate in the fraudulent activities [8][9][12]. - The scheme exploited the reimbursement policies that limited adult hemophilia patients to medication use only during bleeding episodes, creating a loophole that allowed for excessive and unnecessary prescriptions [2][20][21]. Group 2: Patient Experiences and Impacts - Hemophilia patients, particularly those with severe conditions, relied on medications like recombinant factor VIII to manage their health, often leading to a high frequency of prescriptions [5][9][34]. - The fraudulent practices have resulted in patients facing difficulties in obtaining necessary medications, as hospitals have become more cautious in prescribing due to the legal implications of the fraud cases [33][34]. - The article highlights the emotional and physical toll on patients, who now struggle to access their medications and face stigma associated with the fraud allegations [33][34]. Group 3: Regulatory and Policy Implications - The case has drawn attention to the discrepancies between healthcare policies and the best treatment practices for hemophilia, particularly the need for preventive treatment versus the current reimbursement limitations [2][31]. - Experts argue that the existing healthcare reimbursement policies do not adequately address the needs of hemophilia patients, leading to a conflict between patient care and regulatory compliance [30][31]. - The fraud case has prompted stricter enforcement of healthcare policies, impacting the availability of medications for patients and raising concerns about the future of treatment for hemophilia in the region [33][34].

【#老人为卖过期药成医保诈骗工具人#】#老人为赚零花钱变成医保诈骗帮凶#医保基金是我们所有参保 人共同的看病钱、救命钱。但就是这笔钱，有人把它当做"唐僧肉"，不但通过医保卡大肆敛财，还拉拢 了一大批参保人与之同流合污。这是发生在上海市宝山区一个社区公园里的一幕：一位老人在树荫处停 了下来，但她看起来并不像是来遛弯儿的，神色明显有些紧张。不久，一名中年男子出现，他径直走向 老人，接过了对方递出的一个蓝色袋子，然后便迅速离开。发生在社区公园里这一幕，全都在上海宝山 警方的密切监控之下。这名中年男子叫张某桂，长期非法收购各类药品。而与他碰头的那位老人是年近 七旬的刘阿姨，她交给张某桂的那个蓝色袋子里装的正是一些药品......（央视网） 转自：中国反邪教 （来源：中国反邪教） ...

目前，犯罪嫌疑人吴某某、何某、周某某等11人，分别以诈骗罪和非法吸收公众存款罪移送金牛区人民 检察院审查起诉。 警方提醒，在日常生活中，一旦遇到以"免费医疗""康养旅游""医疗投资""医保养老"等为名，声称可以 返还费用、免费体验、分红返利，并诱导使用医保余额、现金、转账等方式缴纳"会费""投资款""床位 租赁费"的，务必提高警惕。切勿轻信所谓"高额回报""保本付息"的承诺，不轻易动用个人医保账户资 金或向外转账。 近日，四川成都公安机关对外公布，该市金牛区分局成功打掉一个特大医保诈骗犯罪团伙，该案涉及虚 开住院记录"住院病人"2700余人、套刷门诊统筹基金1000余人，涉案金额达1500余万元。 成都市公安局金牛区公安分局刑事侦查大队民警何应志介绍，2025年初，该局接到辖区有涉嫌欺诈骗保 的相关线索后，迅速组建专案组开展侦查工作。经查，自2023年5月以来，犯罪嫌疑人吴某某、周某 某、何某、张某某等人，依托团伙名下掌握的健康管理公司开展虚假宣传，以缴纳会费成为公司会员可 返还费用、提供免费旅游和免费医疗为噱头，吸引老年人到该团伙掌握的中医馆，通过虚开药品清单、 空开住院记录、空刷国家医保统筹基金等虚假方式 ...

Core Viewpoint - A criminal gang in Chengdu has been targeting the elderly by using a "traditional Chinese medicine clinic" as a front to illegally solicit public deposits, resulting in over 3,500 elderly victims and more than 36 million yuan in fraudulent funds [3][4][7]. Group 1: Criminal Activities - The gang used free foot baths and egg giveaways to lure elderly individuals into investing in health and wellness services [3][4]. - They engaged in fraudulent activities such as issuing fake medical prescriptions, creating false hospitalization records, and misusing national health insurance funds [4][5]. - The investigation revealed that over 2,700 individuals had false hospitalization records, and more than 1,000 had their outpatient insurance funds fraudulently accessed, amounting to approximately 15 million yuan [4][7]. Group 2: Investment Scheme - The gang established a multi-tiered membership system, with fees ranging from 120 yuan for basic membership to higher tiers promising monthly returns of 3% (annualized 36%) on investments [7][8]. - The scheme initially paid out returns to create a false sense of security among the elderly, funded by both fraudulent health insurance claims and new member fees [7][8]. - The largest individual investment reported was over 1.2 million yuan, with some victims being over 80 years old [8]. Group 3: Legal Actions - Eleven suspects, including key figures in the gang, have been prosecuted for fraud and illegal public deposit solicitation [9].

本报讯（记者蒋杰 通讯员方芳 许谈青山）明明因交通事故受伤，却在就医时谎称在家摔伤，意图使 部分医疗费用通过医保基金结算。2025年11月，经浙江省象山县检察院提起公诉，法院以诈骗罪分别判 处被告人张某某、陆某发、陆某顺有期徒刑七个月，缓刑一年，各并处罚金3000元。 考虑到陈阿婆伤势严重，陆某顺担心张某某事后反悔，于是选择先报警确定交通事故责任。经认定，小 井负事故全部责任。责任明确后，陆某发父子同意了张某某的请求，在医生询问受伤原因时隐瞒了陈阿 婆被他人撞伤的事实，谎称是摔伤住院，无第三方责任及赔偿。2023年5月至6月，陆某发父子用陈阿婆 的医保卡结算，骗取国家医保统筹基金2.3万余元。 2025年9月9日，象山县医疗保障局发现陆某发父子明知陈阿婆在交通事故中受伤，却仍使用医保报销， 遂向公安机关移送该案线索。同日，公安机关对陆某发、陆某顺涉嫌诈骗案立案侦查。9月22日，陈阿 婆向医保中心退回全部外伤报销款。 案件被移送象山县检察院审查后，办案检察官发现，向医院隐瞒交通事故的建议是张某某提出的，陆某 发和陆某顺则明知交通事故不能用医保结算，仍谎称陈阿婆在家摔伤并进行报销，3人的行为应当认定 为合谋骗取医 ...

Core Points - A pharmaceutical representative from a certain company was sentenced for fraud after altering patient genetic test reports to meet sales targets, leading to misuse of targeted cancer medication and resulting in a loss of 27,540 yuan from the medical insurance fund [1][2] Group 1: Legal Proceedings - The court found that the representative's actions constituted fraud under Article 266 of the Criminal Law of the People's Republic of China, as he aimed to illegally occupy state medical insurance funds [2] - The representative was sentenced to eight months in prison and fined 7,000 yuan, with a requirement to return the illegal gains to the medical insurance fund [2] Group 2: Industry Implications - The case highlights the critical importance of adhering to drug usage guidelines, particularly for targeted cancer therapies, which require strict compliance with indications and genetic mutation conditions to ensure effective treatment [2] - The incident serves as a warning to the industry about the severe consequences of violating ethical standards and regulations, emphasizing that crossing legal boundaries can lead to significant legal repercussions [2]

Core Points - The Sichuan Provincial Medical Insurance Bureau announced the successful investigation of a major medical insurance fraud case involving five medical institutions, including Chengdu Jiuxing Kidney Hospital and Chengdu Gaoxin Bolin Hospital, with a total fraud amount of 48.08 million yuan [1] - The investigation led to the termination of medical insurance agreements with the involved institutions, the detention of 35 individuals, and the approval of arrests for 16 individuals [1][4] - Longsheng Medical, a well-known national dialysis chain, operates over 100 hospitals and centers across 15 provinces, providing services to more than 17,000 dialysis patients [2] Medical Institutions Involved - Chengdu Jiuxing Kidney Hospital and Chengdu Gaoxin Bolin Hospital are part of Longsheng Medical, which has been implicated in fraudulent activities such as selling "return flow drugs" and offering free dialysis [1][2] - Following the fraud investigation, Chengdu Jiuxing Kidney Hospital has reportedly ceased operations, while Chengdu Gaoxin Bolin Hospital has been rebranded as Chengdu Gao Xin South Hospital, which is currently operational [4][5] Regulatory Actions - The National Medical Insurance Administration has issued a notice to address fraudulent practices in the dialysis sector, emphasizing the need for medical institutions to charge based on actual services provided and prohibiting misleading practices such as "free treatment" [3] - The Sichuan Provincial Medical Insurance Bureau has recovered 4.89 million yuan in principal and penalties from the involved institutions and has suspended payments totaling 70.41 million yuan [4]

Core Viewpoint - The company Shenzhou Cell is embroiled in a series of medical insurance fraud cases involving its product, Anjain, which is a recombinant human coagulation factor VIII for hemophilia A patients. Investigations are ongoing, and several patients and sales representatives are implicated in fraudulent activities related to insurance claims [1][4][5]. Group 1: Company Overview - Shenzhou Cell's Anjain is the first domestically approved recombinant human coagulation factor VIII in China, launched in 2021, primarily for controlling and preventing bleeding in hemophilia A patients aged 12 and older [2]. - The company claims to adhere to legal and compliance standards, emphasizing that the actions of individual sales representatives do not reflect the overall operational strategy of the company [4][20]. - Following the launch of Anjain, the price of recombinant factor VIII has decreased by nearly 50% due to national drug procurement policies [4]. Group 2: Fraud Allegations - The allegations involve Shenzhou Cell's sales team collaborating with patients to fraudulently obtain insurance reimbursements by misrepresenting medical conditions, leading to significant financial gains from the insurance fund [5][11]. - A specific case highlighted that a patient fraudulently obtained over 1.19 million yuan in reimbursements, with the company allegedly providing a 4% rebate on the medication costs to patients [5][19]. - The legal framework stipulates that adult hemophilia patients are only eligible for insurance reimbursement when they exhibit bleeding symptoms, making the fraudulent claims particularly egregious [8][11]. Group 3: Market Impact - Anjain has rapidly gained market share, becoming the leading product in its category within three years of its launch, attributed to its lower price compared to foreign competitors [16]. - The company has established a charitable assistance program that allows patients to receive treatment at no cost, effectively covering the out-of-pocket expenses through partnerships with charitable organizations [17][20]. - The sales strategy has reportedly enabled patients to receive not only free treatment but also cash rebates, creating a controversial but effective market penetration model [18][19]. Group 4: Legal and Compliance Issues - Legal experts indicate that the sales representatives may face significant legal consequences, as their actions reflect a clear understanding of the fraudulent nature of their activities, despite claims of merely following company directives [15][21]. - The company has publicly stated its commitment to compliance and has denied any involvement in fraudulent activities, asserting that any misconduct by individual employees does not represent the company's practices [4][20].

Core Insights - The Shanghai police have dismantled a healthcare fraud ring involving a designated medical institution, which has committed over 50,000 fraudulent claims amounting to more than 120 million yuan in two years [1][13]. Group 1: Fraud Scheme Details - The fraud was orchestrated by the Yiyang Traditional Chinese Medicine Hospital, where internal staff colluded with external pharmaceutical companies to submit false claims [3][9]. - Investigations revealed that many insured individuals did not actually visit the hospital, yet their records showed multiple prescriptions and treatments [3][9]. - A specific employee, Zhao, was noted for bringing numerous neighbors to the hospital, resulting in over 300 visits in just six months [5]. Group 2: Investigation Findings - The police found that during visits, patients were not properly examined; instead, they were simply asked to sign and pay without any consultation [7]. - Data comparisons indicated that while only 2 to 3 patients were present, records showed over 10 visits, indicating a systematic fraud operation [9]. - Some staff members were involved in swapping expensive herbal medicines for cheaper alternatives, further complicating the fraud [11]. Group 3: Legal Actions and Outcomes - Following the identification of the fraud ring's structure, a major operation in October led to the arrest of 34 suspects, with additional arrests of 56 insured individuals in April [13]. - The fraud ring was led by a figure named Yan, who coordinated with stakeholders from the involved medical institutions to execute the fraudulent activities [13].

Group 1 - The article highlights the serious issue of healthcare fraud in Shanghai, particularly involving illegal resale of medications acquired through the medical insurance system [1][2] - In 2025, Shanghai authorities dismantled seven healthcare fraud rings, arresting over 130 suspects and involving more than 14 million yuan in fraudulent activities [2] - A specific case involved a network where medications were purchased at significantly reduced prices (as low as 10 yuan) from insured individuals and then resold at higher prices, creating a comprehensive illegal supply chain [3][4] Group 2 - The fraud operations often targeted elderly individuals, with perpetrators posing as second-hand goods collectors to encourage them to sell their prescribed medications [6][8] - Two private Chinese medicine clinics were found to have engaged in fraudulent practices, including excessive billing for services not rendered and manipulation of medication records [10][11] - A significant fraud ring led by a figure named Yan was uncovered, with over 50,000 fraudulent claims amounting to more than 12 million yuan in total [12]